NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-08-31
Reading ISRG? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Intuitive Surgical grows da Vinci procedures about 16% yearly. Profit margins stay near 68%. The company actively buys back shares, returning value. It leads in robotic surgery with strong demand.
Growth may slow due to below-consensus forecasts. Margin pressure could rise from reuse concerns. The stock is expensive with a high price-to-earnings ratio.
The price is about 8% above our fair value near $396. Analysts expect 16% revenue growth, which the market largely reflects. Our fair value is 30% below the Street median, showing some valuation caution.
Breaks if: procedure growth falls below 10% YoY next year
Focus on expanding the number of da Vinci procedures performed globally.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on increasing procedure volume and maintaining margins. The current thesis state is intact, reflecting strong financial performance despite some near-term risks.
The market currently prices ISRG at a premium compared to peers, reflecting a justified valuation. There is a slight expectations gap, indicating that while the company is seen as strong, there are concerns about execution quality.
Management has shown strong execution in increasing da Vinci procedure volume and controlling operating expenses. However, the non-GAAP gross profit margin has a mixed status, which could impact future performance.
The long-term thesis hinges on the ability to maintain growth in procedure volume and manage expenses effectively. Additionally, external factors like sector performance and economic conditions will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company reported an increase in da Vinci procedure volume, which supports the thesis. However, Johnson & Johnson's recent FDA approval poses a competitive threat to ISRG's procedures.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: gross margin falls below 66% next year
Breaks if: share repurchases drop below $500M per quarter next year
In the next 1-3 years, ISRG's performance will depend on its execution and external market conditions. Not investment advice.
